You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAmiodarone
Accession NumberDB01118  (APRD00288)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. [PubChem]
Structure
Thumb
Synonyms
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
Amiodarona
Amiodarone
Amiodaronum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmiodaroneTablet200 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
AmiodaroneTablet200 mgOralSanis Health Inc2011-06-10Not applicableCanada
AmiodaroneTablet200 mgOralSorres Pharma Inc2009-06-232014-06-20Canada
Amiodarone for Injection 50mg/mlSolution50 mgIntravenousTeva Canada Limited2004-04-21Not applicableCanada
Amiodarone Hydrochloride for InjectionSolution50 mgIntravenousFresenius Kabi Canada Ltd2002-04-23Not applicableCanada
Amiodarone Hydrochloride for InjectionSolution50 mgIntravenousHospira Healthcare Corporation2002-08-29Not applicableCanada
Amiodarone Hydrochloride for InjectionLiquid50 mgIntravenousSandoz Canada Incorporated2000-06-14Not applicableCanada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan Pharmaceuticals Ulc2012-10-242016-07-06Canada
Amiodarone Hydrochloride InjectionSolution50 mgIntravenousMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Amiodarone OmegaSolution50 mgIntravenousOmega Laboratories LtdNot applicableNot applicableCanada
Amiodarone SyringeSolution50 mgIntravenousSandoz Canada Incorporated2015-08-12Not applicableCanada
Ava-amiodaroneTablet200 mgOralAvanstra Inc2011-09-152014-08-21Canada
CordaroneTablet200 mg/1OralWyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.1985-12-01Not applicableUs
CordaroneTablet200 mgOralPfizer Canada Inc1994-12-312016-07-12Canada
Cordarone Intravenous - Liq IV 50mg/mlLiquid50 mgIntravenousWyeth Ayerst Canada Inc.1995-12-312003-04-17Canada
Cordarone Tab 200mgTablet200 mgOralAyerst Laboratories1986-12-311996-09-10Canada
Dom-amiodaroneTablet200 mgOralDominion Pharmacal2004-04-15Not applicableCanada
Dom-amiodaroneTablet100 mgOralDominion PharmacalNot applicableNot applicableCanada
Jamp-amiodaroneSolution50 mgIntravenousJamp Pharma CorporationNot applicableNot applicableCanada
Mylan-amiodaroneTablet200 mgOralMylan Pharmaceuticals Ulc1999-08-04Not applicableCanada
NexteroneInjection, solution1.5 mg/mLIntravenousBaxter Healthcare Corporation2010-11-16Not applicableUs
NexteroneInjection, solution1.8 mg/mLIntravenousBaxter Healthcare Corporation2010-11-16Not applicableUs
Ntp-amiodaroneTablet200 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-amiodaroneTablet200 mgOralNu Pharm IncNot applicableNot applicableCanada
Pendo-amiodaroneTablet200 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-amiodaroneTablet100 mgOralPharmel IncNot applicableNot applicableCanada
PHL-amiodaroneTablet200 mgOralPharmel Inc2002-05-27Not applicableCanada
PMS-amiodaroneTablet100 mgOralPharmascience Inc2007-04-03Not applicableCanada
PMS-amiodaroneTablet200 mgOralPharmascience Inc2000-07-28Not applicableCanada
Pro-amiodarone - 200Tablet200 mgOralPro Doc Limitee2008-07-04Not applicableCanada
Ratio-amiodaroneTablet200 mgOralRatiopharm Inc Division Of Teva Canada Limited1999-05-122014-09-19Canada
Ratio-amiodarone I.V.Liquid50 mgIntravenousRatiopharm Inc Division Of Teva Canada Limited2000-09-272008-08-01Canada
Riva-amiodaroneTablet200 mgOralLaboratoire Riva Inc2003-03-05Not applicableCanada
Sandoz AmiodaroneTablet200 mgOralSandoz Canada Incorporated2001-08-21Not applicableCanada
Teva-amiodaroneTablet200 mgOralTeva Canada Limited1999-03-29Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClTablet400 mg/1OralMayne Pharma Inc.2013-01-01Not applicableUs
Amiodarone HClTablet200 mg/1OralMayne Pharma Inc.2013-01-01Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousGeneral Injectables & Vaccines, Inc2012-06-06Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-03-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralMc Kesson Packaging A Business Unit Of Mc Kesson Corporation2008-03-01Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralMajor Pharmaceuticals2009-08-10Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousHospira, Inc.2013-11-25Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralCardinal Health1998-11-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralPhysicians Total Care, Inc.2002-04-22Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralREMEDYREPACK INC.2014-08-01Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousSagent Pharmaceuticals2013-07-15Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralEon Labs, Inc.1998-12-23Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralGolden State Medical Supply, Inc.2001-03-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralA S Medication Solutions2009-08-10Not applicableUs
Amiodarone HydrochlorideInjection, solution, concentrate50 mg/mLIntravenousGeneral Injectables & Vaccines, Inc.2010-03-01Not applicableUs
Amiodarone HydrochlorideTablet100 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2001-03-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralA S Medication Solutions1998-11-30Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousHospira, Inc.2013-11-25Not applicableUs
Amiodarone HydrochlorideTablet400 mg/1OralAv Kare, Inc.2016-03-18Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralApotex Corp2008-11-06Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralAmerican Health Packaging2009-09-25Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralLake Erie Medical DBA Quality Care Products LLC1998-11-30Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousREMEDYREPACK INC.2015-08-19Not applicableUs
Amiodarone HydrochlorideTablet300 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2003-12-02Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralCadila Healthcare Limited2009-08-10Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousHospira, Inc.2002-10-18Not applicableUs
Amiodarone HydrochlorideInjection50 mg/mLIntravenousGENERAL INJECTABLES AND VACCINES, INC.2014-09-02Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralTeva Pharmaceuticals USA Inc1998-11-30Not applicableUs
Amiodarone HydrochlorideInjection50 mg/mLIntravenousWockhardt Limited2008-10-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralA S Medication Solutions1998-11-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1998-12-23Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralREMEDYREPACK INC.2015-05-12Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralMylan Institutional Inc.1999-11-01Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralREMEDYREPACK INC.2009-09-15Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousAPP Pharmaceuticals, LLC2003-01-28Not applicableUs
Amiodarone HydrochlorideTablet400 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2002-11-29Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousMylan Institutional LLC2002-10-14Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Amiodarone HydrochlorideInjection, solution50 mg/mLIntravenousWest Ward Pharmaceuticals Corp2008-02-25Not applicableUs
Amiodarone HydrochlorideInjection50 mg/mLIntravenousWockhardt Limited2008-10-30Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralAurobindo Pharma Limited2016-06-03Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralRebel Distributors Corp2009-08-10Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralCardinal Health2009-09-25Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralZydus Pharmaceuticals (USA) Inc.2009-08-10Not applicableUs
Amiodarone HydrochlorideTablet200 mg/1OralMc Kesson Contract Packaging2012-01-03Not applicableUs
Apo-amiodarone TabletsTablet200 mgOralApotex Inc2003-09-05Not applicableCanada
PaceroneTablet200 mg/1OralAphena Pharma Solutions Tennessee, Llc2011-01-19Not applicableUs
PaceroneTablet100 mg/1OralUpsher Smith Laboratories, Inc.2011-01-19Not applicableUs
PaceroneTablet200 mg/1OralRx Pak Division Of Mc Kesson Corporation2014-04-28Not applicableUs
PaceroneTablet200 mg/1OralCardinal Health2011-01-19Not applicableUs
PaceroneTablet200 mg/1OralPhysicians Total Care, Inc.2008-10-22Not applicableUs
PaceroneTablet200 mg/1OralUpsher Smith Laboratories, Inc.2011-01-19Not applicableUs
PaceroneTablet400 mg/1OralUpsher Smith Laboratories, Inc.2000-06-30Not applicableUs
PaceroneTablet200 mg/1OralAvera Mc Kennan Hospital2015-09-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amiodarone HClInjection, solution1.8 mg/mLIntravenousCantrell Drug Company2011-08-01Not applicableUs
International Brands
NameCompany
Amio-Aqueous IVNot Available
AratacNot Available
ArycorNot Available
AtlansilNot Available
TachyraNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Amiodarone Hydrochloride
Thumb
  • InChI Key: ITPDYQOUSLNIHG-UHFFFAOYSA-N
  • Monoisotopic Mass: 681.000358378
  • Average Mass: 681.773
DBSALT000355
Categories
UNIIN3RQ532IUT
CAS number1951-25-3
WeightAverage: 645.3116
Monoisotopic: 645.023680639
Chemical FormulaC25H29I2NO3
InChI KeyIYIKLHRQXLHMJQ-UHFFFAOYSA-N
InChI
InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3
IUPAC Name
{2-[4-(2-butyl-1-benzofuran-3-carbonyl)-2,6-diiodophenoxy]ethyl}diethylamine
SMILES
CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Pharmacology
IndicationIntravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.
Structured Indications
PharmacodynamicsAmiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.
Mechanism of actionThe antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium voltage-gated channel subfamily H member 2Proteinyes
inhibitor
HumanQ12809 details
Beta-1 adrenergic receptorProteinyes
antagonist
HumanP08588 details
Voltage-dependent T-type calcium channel subunit alpha-1HProteinunknown
inhibitor
HumanO95180 details
Voltage-dependent calcium channel subunit alpha-2/delta-2Proteinyes
inhibitor
HumanQ9NY47 details
Related Articles
AbsorptionSlow and variable (about 20 to 55% of an oral dose is absorbed).
Volume of distributionNot Available
Protein binding>96%
Metabolism

Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

SubstrateEnzymesProduct
Amiodarone
N-desethylamiodaroneDetails
Route of eliminationAmiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.
Half life58 days (range 15-142 days)
Clearance
  • 90-158 mL/h/kg [Healthy with a single dose IV (5 mg/kg over 15 min)]
  • 100 mL/h/kg [Normal subjects > 65 yrs]
  • 150 mL/h/kg [younger subjects]
  • 220 and 440 mL/h/kg [patients with VT and VF]
ToxicityIntravenous, mouse: LD50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Amiodarone Action PathwayDrug actionSMP00665
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Potassium voltage-gated channel subfamily H member 2
Gene symbol: KCNH2
UniProt: Q12809
Not AvailableMiRP1KCNE2Channels formed with mutant MiRP1 subunits and HERG showed slower activation, faster deactivation, and increased drug sensitivity and is associated with cardiac arrhythmia.10219239
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Amiodarone.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Amiodarone.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Amiodarone.Experimental, Illicit
AbirateroneThe serum concentration of Amiodarone can be increased when it is combined with Abiraterone.Approved
AcebutololAmiodarone may increase the bradycardic activities of Acebutolol.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Amiodarone.Approved
AcenocoumarolAmiodarone may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Amiodarone.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Acetazolamide.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Amiodarone.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Amiodarone.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Amiodarone.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Amiodarone.Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Amiodarone.Approved
Agalsidase betaThe therapeutic efficacy of Agalsidase beta can be decreased when used in combination with Amiodarone.Approved, Investigational
AjmalineAmiodarone may increase the QTc-prolonging activities of Ajmaline.Approved
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Amiodarone.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiodarone.Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Amiodarone.Experimental
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Amiodarone.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Amiodarone.Approved, Investigational
AliskirenThe metabolism of Aliskiren can be decreased when combined with Amiodarone.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Amiodarone.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Amiodarone.Approved
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Amiodarone.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Amiodarone.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Amiodarone.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
AlprenololAmiodarone may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Amiodarone.Approved
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Amiodarone.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Amiodarone.Approved
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Amiodarone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Amiodarone.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Amiodarone.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Amiodarone.Approved
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Amiodarone.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Amiodarone.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Amiodarone.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Amiodarone.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Amiodarone.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amiodarone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Amiodarone.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Amiodarone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Amiodarone.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Amiodarone.Approved
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Amiodarone.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Amiodarone.Approved
AnvirzelThe serum concentration of Anvirzel can be increased when it is combined with Amiodarone.Investigational
Aop200704Amiodarone may increase the bradycardic activities of Aop200704.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Amiodarone.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Amiodarone.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Amiodarone.Approved, Investigational
AprepitantThe serum concentration of Amiodarone can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Amiodarone.Approved
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Amiodarone.Experimental
ArformoterolArformoterol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Amiodarone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
ArmodafinilThe metabolism of Amiodarone can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololAmiodarone may increase the bradycardic activities of Arotinolol.Approved
Arsenic trioxideAmiodarone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherAmiodarone may increase the QTc-prolonging activities of Artemether.Approved
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Amiodarone resulting in a loss in efficacy.Approved
AsenapineAmiodarone may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Amiodarone.Approved, Withdrawn
AtazanavirThe serum concentration of Amiodarone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAmiodarone may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Amiodarone.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Amiodarone.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Amiodarone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Amiodarone.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Amiodarone.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Amiodarone.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Amiodarone.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Amiodarone.Experimental
BarbitalBarbital may increase the hypotensive activities of Amiodarone.Illicit
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Amiodarone.Approved
BeclomethasoneThe serum concentration of Beclomethasone can be increased when it is combined with Amiodarone.Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Amiodarone.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Amiodarone.Approved
BefunololAmiodarone may increase the bradycardic activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Amiodarone.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Amiodarone.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Amiodarone.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Amiodarone.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Amiodarone.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Amiodarone.Approved, Withdrawn
BeractantAmiodarone may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Amiodarone.Approved, Vet Approved
BetaxololAmiodarone may increase the bradycardic activities of Betaxolol.Approved
BevantololAmiodarone may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Amiodarone.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Amiodarone.Approved
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Amiodarone.Approved
BisoprololAmiodarone may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Amiodarone can be increased when it is combined with Boceprevir.Approved
BopindololAmiodarone may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Amiodarone.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Amiodarone.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Amiodarone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone.Approved
BretyliumBretylium may increase the bradycardic activities of Amiodarone.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Amiodarone.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Amiodarone.Approved
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Amiodarone.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Amiodarone.Approved, Illicit
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Amiodarone.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Amiodarone.Approved
BucindololAmiodarone may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved
BudesonideThe metabolism of Budesonide can be decreased when combined with Amiodarone.Approved
BufuralolAmiodarone may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Amiodarone.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Amiodarone.Approved, Investigational
BupranololAmiodarone may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Amiodarone.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Amiodarone.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Amiodarone.Approved, Investigational
BusulfanThe metabolism of Busulfan can be decreased when combined with Amiodarone.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Amiodarone.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Amiodarone.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Amiodarone.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Amiodarone.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Amiodarone.Approved, Nutraceutical
CalfactantAmiodarone may increase the bradycardic activities of Calfactant.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Amiodarone.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Amiodarone.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Amiodarone.Approved
CapecitabineThe metabolism of Amiodarone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Amiodarone.Approved
CarbamazepineThe metabolism of Amiodarone can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Amiodarone is combined with Carbetocin.Approved
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Amiodarone.Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Amiodarone.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Amiodarone.Approved
CarteololAmiodarone may increase the bradycardic activities of Carteolol.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Amiodarone.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Amiodarone.Approved, Investigational
CeliprololAmiodarone may increase the bradycardic activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Amiodarone.Approved, Vet Approved
CeritinibAmiodarone may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Amiodarone.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Amiodarone.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Amiodarone.Approved
ChloramphenicolThe metabolism of Amiodarone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Amiodarone.Approved, Illicit
ChloroquineChloroquine may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amiodarone.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Amiodarone.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Amiodarone.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Amiodarone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Amiodarone.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
CholestyramineThe bioavailability of Amiodarone can be decreased when combined with Cholestyramine.Approved
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Amiodarone.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amiodarone.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Amiodarone.Approved
CimetidineThe serum concentration of Amiodarone can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Amiodarone.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Amiodarone.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Amiodarone.Approved
CitalopramCitalopram may increase the QTc-prolonging activities of Amiodarone.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
ClemastineThe metabolism of Amiodarone can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Amiodarone.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Amiodarone.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Amiodarone.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Amiodarone.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Amiodarone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Clofarabine.Approved, Investigational
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Amiodarone.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Amiodarone.Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Amiodarone.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Amiodarone.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Amiodarone.Approved, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Amiodarone.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Amiodarone.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Amiodarone.Approved, Illicit
ClotrimazoleThe metabolism of Amiodarone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Amiodarone.Approved
CobicistatThe serum concentration of Amiodarone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Amiodarone.Approved
CocaineThe metabolism of Cocaine can be decreased when combined with Amiodarone.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Amiodarone.Approved, Illicit
Coenzyme Q10The metabolism of Coenzyme Q10 can be decreased when combined with Amiodarone.Experimental
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Amiodarone.Approved
ColesevelamThe bioavailability of Amiodarone can be decreased when combined with Colesevelam.Approved
ColestipolThe bioavailability of Amiodarone can be decreased when combined with Colestipol.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Amiodarone.Approved, Investigational
Conjugated Equine EstrogensThe metabolism of Conjugated Equine Estrogens can be decreased when combined with Amiodarone.Approved
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Amiodarone.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Amiodarone.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Amiodarone.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Amiodarone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe metabolism of Cytarabine can be decreased when combined with Amiodarone.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.Approved
DabrafenibThe serum concentration of Amiodarone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirDaclatasvir may increase the bradycardic activities of Amiodarone.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Amiodarone.Approved
DantroleneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Amiodarone.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Amiodarone.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Amiodarone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Amiodarone.Approved, Investigational
DarunavirThe serum concentration of Amiodarone can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Amiodarone can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Amiodarone.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Amiodarone.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Amiodarone.Approved
DeferasiroxThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Amiodarone.Approved
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Amiodarone.Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Amiodarone.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Amiodarone.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Amiodarone.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Amiodarone.Approved
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Amiodarone.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Amiodarone.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Amiodarone.Approved
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Amiodarone.Vet Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Amiodarone.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Amiodarone.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Amiodarone.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
DiazepamThe metabolism of Diazepam can be decreased when combined with Amiodarone.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Amiodarone.Approved, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Amiodarone.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Amiodarone.Approved
DicoumarolAmiodarone may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Amiodarone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Amiodarone.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Amiodarone.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Amiodarone.Approved
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Amiodarone.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Amiodarone.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Amiodarone.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Amiodarone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Amiodarone.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Amiodarone.Illicit
DiltiazemDiltiazem may increase the bradycardic activities of Amiodarone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Amiodarone.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Amiodarone.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Amiodarone.Approved
DisopyramideAmiodarone may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Amiodarone.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Amiodarone.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Amiodarone.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Amiodarone.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Amiodarone.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Amiodarone.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Amiodarone.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Amiodarone.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Amiodarone.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Amiodarone.Approved, Investigational
DoxycyclineThe metabolism of Amiodarone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Amiodarone.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Amiodarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Amiodarone.Approved
DuloxetineAmiodarone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Amiodarone.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Amiodarone.Approved
EfavirenzThe metabolism of Efavirenz can be decreased when combined with Amiodarone.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Amiodarone.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Amiodarone.Approved
ElvitegravirThe metabolism of Elvitegravir can be decreased when combined with Amiodarone.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Amiodarone.Approved
EnalaprilThe metabolism of Enalapril can be decreased when combined with Amiodarone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Amiodarone.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Amiodarone.Investigational
EnzalutamideThe serum concentration of Amiodarone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Amiodarone.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Amiodarone.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Amiodarone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Amiodarone.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Amiodarone.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Amiodarone.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Amiodarone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Amiodarone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Amiodarone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Amiodarone.Approved
EribulinEribulin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Amiodarone.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
EscitalopramAmiodarone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Amiodarone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Amiodarone.Investigational
EsmololAmiodarone may increase the bradycardic activities of Esmolol.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Amiodarone.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Amiodarone.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be decreased when combined with Amiodarone.Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Amiodarone.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Amiodarone.Approved, Vet Approved
EstroneThe metabolism of Estrone can be decreased when combined with Amiodarone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Amiodarone.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Amiodarone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amiodarone.Approved
EthanolThe metabolism of Ethanol can be decreased when combined with Amiodarone.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Amiodarone.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Amiodarone.Approved
Ethyl biscoumacetateAmiodarone may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Amiodarone.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Amiodarone.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Amiodarone.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Amiodarone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Amiodarone.Approved, Investigational
EtravirineThe serum concentration of Amiodarone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Amiodarone.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Amiodarone.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Amiodarone.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Amiodarone.Approved
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Amiodarone.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Amiodarone.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Amiodarone.Approved
FelodipineThe metabolism of Felodipine can be decreased when combined with Amiodarone.Approved, Investigational
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Amiodarone.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fenoldopam.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Amiodarone.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Amiodarone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Amiodarone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Amiodarone.Approved
FimasartanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fimasartan.Approved
FinasterideThe metabolism of Finasteride can be decreased when combined with Amiodarone.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Amiodarone.Approved, Investigational
FlecainideAmiodarone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Amiodarone.Approved
FloxuridineThe metabolism of Amiodarone can be decreased when combined with Floxuridine.Approved
fluasteroneThe serum concentration of fluasterone can be increased when it is combined with Amiodarone.Investigational
FluconazoleFluconazole may increase the QTc-prolonging activities of Amiodarone.Approved
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Amiodarone.Approved
FluindioneAmiodarone may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Amiodarone.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Amiodarone.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Amiodarone.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Amiodarone.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Amiodarone.Approved
FluorouracilThe metabolism of Amiodarone can be decreased when combined with Fluorouracil.Approved
FluoxetineFluoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Amiodarone.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Amiodarone.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Amiodarone.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Amiodarone.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Amiodarone.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Amiodarone.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Amiodarone.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Amiodarone.Approved
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Amiodarone.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Amiodarone.Approved
Fluticasone PropionateThe metabolism of Fluticasone Propionate can be decreased when combined with Amiodarone.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Amiodarone.Approved
FluvoxamineThe metabolism of Amiodarone can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Amiodarone.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
FosamprenavirThe serum concentration of Amiodarone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Amiodarone can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Amiodarone.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amiodarone.Approved
FosphenytoinFosphenytoin may increase the QTc-prolonging activities of Amiodarone.Approved
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Amiodarone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Amiodarone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Amiodarone can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Amiodarone.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Amiodarone.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Amiodarone.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Amiodarone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Amiodarone.Approved
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Amiodarone.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Amiodarone.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Amiodarone.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Amiodarone.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Amiodarone.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Amiodarone.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Amiodarone.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Amiodarone.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Amiodarone.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Amiodarone.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Amiodarone.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Amiodarone.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Amiodarone.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Amiodarone.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Amiodarone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Amiodarone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Amiodarone.Approved, Vet Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Amiodarone.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Amiodarone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Amiodarone.Approved, Illicit
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Amiodarone.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Amiodarone.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Amiodarone.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Amiodarone.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Amiodarone.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Amiodarone.Approved
IdelalisibThe serum concentration of Amiodarone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Amiodarone resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Amiodarone.Approved
IloprostThe risk or severity of adverse effects can be increased when Amiodarone is combined with Iloprost.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Amiodarone.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Amiodarone.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Amiodarone.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Amiodarone.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Amiodarone.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Amiodarone.Approved
IndenololAmiodarone may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Amiodarone can be increased when it is combined with Indinavir.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Amiodarone.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Amiodarone.Approved, Investigational
IndoraminThe risk or severity of adverse effects can be increased when Amiodarone is combined with Indoramin.Withdrawn
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Amiodarone.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Amiodarone.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Amiodarone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Amiodarone is combined with Isocarboxazid.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
IsoniazidThe metabolism of Amiodarone can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Amiodarone.Approved
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Amiodarone.Approved, Withdrawn
IsradipineThe metabolism of Isradipine can be decreased when combined with Amiodarone.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Amiodarone.Investigational
ItraconazoleThe metabolism of Itraconazole can be decreased when combined with Amiodarone.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Amiodarone.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Amiodarone.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Amiodarone.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Amiodarone.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Amiodarone.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Amiodarone.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Amiodarone.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Amiodarone.Approved
KetoconazoleThe metabolism of Ketoconazole can be decreased when combined with Amiodarone.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Amiodarone.Approved, Vet Approved
LabetalolAmiodarone may increase the bradycardic activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lacidipine.Approved
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Amiodarone.Approved
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Amiodarone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Amiodarone.Approved, Investigational
LanreotideAmiodarone may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Amiodarone.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Amiodarone.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Amiodarone.Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Amiodarone.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Amiodarone.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Amiodarone.Approved
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Amiodarone.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Amiodarone.Approved
LetrozoleThe metabolism of Letrozole can be decreased when combined with Amiodarone.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Amiodarone.Approved, Investigational
LevobunololAmiodarone may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Amiodarone.Approved
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Amiodarone.Approved
LevodopaAmiodarone may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Amiodarone.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Amiodarone.Approved
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Amiodarone.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Amiodarone is combined with Levosimendan.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Amiodarone.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Amiodarone.Investigational
LidocaineThe metabolism of Lidocaine can be decreased when combined with Amiodarone.Approved, Vet Approved
LidocaineLidocaine may increase the arrhythmogenic activities of Amiodarone.Approved, Vet Approved
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Amiodarone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Amiodarone.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Amiodarone.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Amiodarone.Approved
LithiumLithium may increase the QTc-prolonging activities of Amiodarone.Approved
LofexidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Lofexidine.Approved, Investigational
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Amiodarone.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Amiodarone.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Amiodarone.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Amiodarone.Approved
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Amiodarone.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Amiodarone.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Amiodarone.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Amiodarone.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Amiodarone.Approved, Investigational
LucinactantAmiodarone may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Amiodarone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Amiodarone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Amiodarone.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Amiodarone.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Amiodarone.Approved
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Amiodarone.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Amiodarone.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Amiodarone.Approved
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Amiodarone.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Amiodarone.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Amiodarone.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Amiodarone.Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Amiodarone.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Amiodarone.Approved
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Amiodarone.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Amiodarone.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Amiodarone.Approved, Nutraceutical, Vet Approved
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Amiodarone.Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Amiodarone.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Amiodarone.Investigational, Withdrawn
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Amiodarone.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Amiodarone.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Amiodarone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Amiodarone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Amiodarone.Approved, Illicit
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Amiodarone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Amiodarone.Approved
MethohexitalMethohexital may increase the hypotensive activities of Amiodarone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Amiodarone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Amiodarone.Approved
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Amiodarone.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Amiodarone.Approved, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiodarone.Approved
MethyldopaMethyldopa may increase the bradycardic activities of Amiodarone.Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Amiodarone.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Amiodarone.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Amiodarone.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Amiodarone.Approved, Illicit, Withdrawn
MetipranololAmiodarone may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Amiodarone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Amiodarone.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Amiodarone.Approved
MevastatinThe metabolism of Mevastatin can be decreased when combined with Amiodarone.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Amiodarone.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Amiodarone.Approved
MibefradilThe metabolism of Mibefradil can be decreased when combined with Amiodarone.Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
MidazolamThe metabolism of Midazolam can be decreased when combined with Amiodarone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Amiodarone.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Amiodarone.Approved
MipomersenAmiodarone may increase the hepatotoxic activities of Mipomersen.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Amiodarone.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.Approved
MitotaneThe serum concentration of Amiodarone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Amiodarone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Amiodarone.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Amiodarone.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Amiodarone.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Amiodarone.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Amiodarone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Amiodarone.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Moxonidine.Approved
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Amiodarone.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nabilone.Approved, Investigational
NadololAmiodarone may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Amiodarone can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Amiodarone.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Amiodarone.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Amiodarone.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Amiodarone.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Amiodarone.Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Amiodarone.Approved, Withdrawn
NelfinavirThe serum concentration of Amiodarone can be increased when it is combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Amiodarone.Approved, Investigational
NetupitantThe serum concentration of Amiodarone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Amiodarone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Amiodarone.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Amiodarone.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Amiodarone.Approved, Vet Approved
NicorandilNicorandil may increase the hypotensive activities of Amiodarone.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Amiodarone.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Amiodarone.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Amiodarone.Approved, Investigational
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Amiodarone.Approved
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Amiodarone.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Amiodarone.Approved
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Amiodarone.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Amiodarone.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Amiodarone.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nitric Oxide.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Amiodarone.Approved, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Amiodarone.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Amiodarone.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Amiodarone.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Amiodarone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Amiodarone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Amiodarone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Amiodarone is combined with Obinutuzumab.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Amiodarone.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Amiodarone.Approved
Oleoyl estroneThe serum concentration of Oleoyl estrone can be increased when it is combined with Amiodarone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Amiodarone.Approved, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Amiodarone.Approved
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Amiodarone.Approved
OmbitasvirThe serum concentration of Amiodarone can be increased when it is combined with Ombitasvir.Approved
OmeprazoleThe metabolism of Omeprazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Amiodarone.Approved
OrlistatOrlistat can cause a decrease in the absorption of Amiodarone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Amiodarone.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Amiodarone.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Amiodarone.Approved
OuabainThe serum concentration of Ouabain can be increased when it is combined with Amiodarone.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Amiodarone.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Amiodarone.Approved
OxprenololAmiodarone may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Amiodarone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Amiodarone.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Amiodarone.Approved
PaliperidoneAmiodarone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Amiodarone.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Amiodarone.Approved, Investigational
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Amiodarone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Amiodarone.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Amiodarone.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Amiodarone.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Amiodarone.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Amiodarone.Approved, Investigational
ParitaprevirThe serum concentration of Amiodarone can be increased when it is combined with Paritaprevir.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Amiodarone.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.Approved
Peginterferon alfa-2bThe serum concentration of Amiodarone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololAmiodarone may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidinePentamidine may increase the QTc-prolonging activities of Amiodarone.Approved
PentobarbitalThe metabolism of Amiodarone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Amiodarone.Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Amiodarone.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Amiodarone.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Amiodarone.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Amiodarone.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Amiodarone.Approved, Investigational
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Amiodarone.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Amiodarone.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Amiodarone.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Amiodarone.Approved, Withdrawn
PhenindioneAmiodarone may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Amiodarone can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Amiodarone.Approved
PhenprocoumonAmiodarone may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Phentolamine.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Amiodarone.Approved, Vet Approved
PhenytoinThe serum concentration of Amiodarone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Amiodarone.Approved
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Amiodarone.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Amiodarone.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Amiodarone.Withdrawn
PindololAmiodarone may increase the bradycardic activities of Pindolol.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Amiodarone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Amiodarone.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Amiodarone.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Amiodarone.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Amiodarone.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Amiodarone.Approved
Poractant alfaAmiodarone may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
PractololAmiodarone may increase the bradycardic activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pramipexole.Approved, Investigational
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Amiodarone.Approved
PrasteroneThe metabolism of Prasterone can be decreased when combined with Amiodarone.Approved, Nutraceutical
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Amiodarone resulting in a loss in efficacy.Approved
PravastatinThe metabolism of Pravastatin can be decreased when combined with Amiodarone.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Amiodarone.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Amiodarone.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Amiodarone.Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.Approved
PrednisoloneThe metabolism of Prednisolone can be decreased when combined with Amiodarone.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Amiodarone.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Amiodarone.Experimental
PrimaquinePrimaquine may increase the QTc-prolonging activities of Amiodarone.Approved
PrimidoneThe metabolism of Amiodarone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideAmiodarone may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Amiodarone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Amiodarone.Approved
PromazinePromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Amiodarone.Approved
PropafenoneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
PropranololAmiodarone may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Amiodarone.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Amiodarone.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Amiodarone.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Amiodarone.Approved
PyrimethamineThe metabolism of Amiodarone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Amiodarone.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Amiodarone.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Amiodarone.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Amiodarone.Approved, Investigational
QuinidineAmiodarone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineQuinine may increase the QTc-prolonging activities of Amiodarone.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Amiodarone.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Amiodarone.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Amiodarone.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Amiodarone.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Amiodarone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Amiodarone.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Rasagiline.Approved
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Amiodarone.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Amiodarone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Amiodarone.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Amiodarone.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Amiodarone.Investigational
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Amiodarone.Approved
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Amiodarone.Approved
RifabutinThe metabolism of Amiodarone can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of the active metabolites of Amiodarone can be reduced when Amiodarone is used in combination with Rifampicin resulting in a loss in efficacy.Approved
RifapentineThe metabolism of Amiodarone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Amiodarone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Amiodarone.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Amiodarone.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Amiodarone.Approved, Investigational
RiociguatThe metabolism of Riociguat can be decreased when combined with Amiodarone.Approved
RisperidoneAmiodarone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Amiodarone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Amiodarone.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Amiodarone.Approved, Investigational
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Amiodarone.Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Amiodarone.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Amiodarone.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Amiodarone.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Amiodarone.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Amiodarone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Amiodarone.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Amiodarone.Approved
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Amiodarone.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Amiodarone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Amiodarone is combined with Sacubitril.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Amiodarone.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Amiodarone.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Amiodarone.Approved
SecobarbitalThe metabolism of Amiodarone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Amiodarone.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Amiodarone.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Amiodarone.Approved, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Amiodarone.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Amiodarone.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Amiodarone.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Amiodarone.Approved
SiltuximabThe serum concentration of Amiodarone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Amiodarone.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Amiodarone.Approved
SirolimusThe metabolism of Sirolimus can be decreased when combined with Amiodarone.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Amiodarone.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
Sodium Iodide I-131The therapeutic efficacy of Sodium Iodide I-131 can be decreased when used in combination with Amiodarone.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Amiodarone is combined with Sodium Nitrite.Approved
SofosbuvirSofosbuvir may increase the bradycardic activities of Amiodarone.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Amiodarone.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Amiodarone.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Amiodarone.Approved, Investigational
SotalolAmiodarone may increase the bradycardic activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Amiodarone.Approved
SparteineAmiodarone may increase the QTc-prolonging activities of Sparteine.Experimental
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Amiodarone.Experimental
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Amiodarone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Amiodarone.Approved
St. John's WortThe serum concentration of Amiodarone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Amiodarone can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Amiodarone is combined with Streptokinase.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Amiodarone.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Amiodarone.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Amiodarone.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Amiodarone.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Amiodarone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Amiodarone.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Amiodarone.Approved, Withdrawn
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Amiodarone.Approved
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Amiodarone.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Amiodarone.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Amiodarone.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Amiodarone.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Amiodarone.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Amiodarone.Approved
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Amiodarone.Approved
TasosartanThe metabolism of Tasosartan can be decreased when combined with Amiodarone.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Amiodarone.Experimental
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Amiodarone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Amiodarone.Approved
TegafurThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Amiodarone.Investigational, Withdrawn
TelaprevirThe risk or severity of adverse effects can be increased when Telaprevir is combined with Amiodarone.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Amiodarone.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Amiodarone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Amiodarone.Approved, Investigational
TemazepamThe metabolism of Temazepam can be decreased when combined with Amiodarone.Approved
TemsirolimusThe metabolism of Temsirolimus can be decreased when combined with Amiodarone.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Amiodarone.Approved
TenofovirThe metabolism of Amiodarone can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Amiodarone.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Amiodarone.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Amiodarone.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Amiodarone.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Amiodarone.Withdrawn
TeriflunomideThe serum concentration of Amiodarone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Amiodarone.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Amiodarone.Approved, Investigational
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Amiodarone.Approved
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Amiodarone.Approved, Vet Approved
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Theophylline can be decreased when combined with Amiodarone.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Amiodarone.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Amiodarone.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.Approved
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Amiodarone.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Amiodarone.Approved
TiagabineThe metabolism of Tiagabine can be decreased when combined with Amiodarone.Approved
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Amiodarone resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Amiodarone.Approved
TimololAmiodarone may increase the bradycardic activities of Timolol.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Amiodarone.Approved, Investigational
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Amiodarone.Approved
TipranavirThe serum concentration of Amiodarone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Amiodarone.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Amiodarone.Approved
TocilizumabThe serum concentration of Amiodarone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Amiodarone.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Amiodarone.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amiodarone is combined with Tolcapone.Approved, Withdrawn
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Amiodarone.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Amiodarone.Approved
TopiramateThe metabolism of Amiodarone can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Amiodarone.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Amiodarone.Approved
ToremifeneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Amiodarone.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Amiodarone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Amiodarone.Approved
TranylcypromineThe metabolism of Amiodarone can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Amiodarone.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Amiodarone.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Amiodarone.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Amiodarone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Amiodarone.Approved
TriazolamThe metabolism of Triazolam can be decreased when combined with Amiodarone.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Amiodarone.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Amiodarone.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Amiodarone.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Amiodarone.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Amiodarone.Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Amiodarone.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Amiodarone.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Amiodarone.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Amiodarone.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Amiodarone.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Amiodarone.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Amiodarone.Approved, Investigational
VandetanibAmiodarone may increase the QTc-prolonging activities of Vandetanib.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Amiodarone.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Amiodarone.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Amiodarone.Approved
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Amiodarone.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Amiodarone.Approved
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Amiodarone.Approved
VerapamilVerapamil may increase the bradycardic activities of Amiodarone.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Amiodarone.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Amiodarone.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Amiodarone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Amiodarone.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Amiodarone.Approved, Investigational
VincristineThe metabolism of Vincristine can be decreased when combined with Amiodarone.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Amiodarone.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Amiodarone.Approved, Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Amiodarone.Approved
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Amiodarone.Approved
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Amiodarone.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Amiodarone.Approved
WarfarinAmiodarone may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Amiodarone.Approved, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Amiodarone.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Amiodarone.Approved
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Amiodarone.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Amiodarone.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Amiodarone.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Amiodarone.Approved, Investigational, Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Amiodarone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Amiodarone.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Amiodarone.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Amiodarone.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Amiodarone.Approved
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Amiodarone.Approved, Investigational
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take without regard to meals.
References
Synthesis Reference

DrugSyn.org

US3248401
General References
  1. DELTOUR G, BINON F, TONDEUR R, GOLDENBERG C, HENAUX F, SION R, DERAY E, CHARLIER R: [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:247-54. [PubMed:14026835 ]
  2. CHARLIER R, DELTOUR G, TONDEUR R, BINON F: [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta-N-diethylaminoethoxybenzoyl)-benzofuran]. Arch Int Pharmacodyn Ther. 1962 Sep 1;139:255-64. [PubMed:14020244 ]
  3. Singh BN, Vaughan Williams EM: The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970 Aug;39(4):657-67. [PubMed:5485142 ]
  4. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ, Lazzari JO, Elizari MV: Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976 Dec;38(7):934-44. [PubMed:793369 ]
  5. Rosenbaum MB, Chiale PA, Haedo A, Lazzari JO, Elizari MV: Ten years of experience with amiodarone. Am Heart J. 1983 Oct;106(4 Pt 2):957-64. [PubMed:6613843 ]
External Links
ATC CodesC01BD01
AHFS Codes
  • 24:04.04.20
PDB EntriesNot Available
FDA labelDownload (545 KB)
MSDSDownload (51.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8615
Caco-2 permeable+0.66
P-glycoprotein substrateSubstrate0.8044
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.5099
CYP450 2C9 substrateNon-substrate0.7959
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7188
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8615
Ames testNon AMES toxic0.5661
CarcinogenicityNon-carcinogens0.7696
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6539 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5932
hERG inhibition (predictor II)Inhibitor0.7638
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1.8 mg/mL
InjectionIntravenous50 mg/mL
Injection, solutionIntravenous50 mg/mL
Injection, solution, concentrateIntravenous50 mg/mL
TabletOral100 mg/1
TabletOral200 mg/1
TabletOral300 mg/1
TabletOral400 mg/1
LiquidIntravenous50 mg
SolutionIntravenous50 mg
Injection, solutionIntravenous1.5 mg/mL
TabletOral100 mg
TabletOral200 mg
Prices
Unit descriptionCostUnit
Amiodarone hcl powder38.98USD g
Pacerone 100 mg tablet7.58USD tablet
Pacerone 400 mg tablet7.43USD tablet
Amiodarone hcl 400 mg tablet6.32USD tablet
Cordarone 200 mg tablet4.78USD tablet
Pacerone 200 mg tablet3.53USD tablet
Amiodarone hcl 200 mg tablet3.37USD tablet
Cordarone 200 mg Tablet2.32USD tablet
Apo-Amiodarone 200 mg Tablet1.3USD tablet
Mylan-Amiodarone 200 mg Tablet1.3USD tablet
Novo-Amiodarone 200 mg Tablet1.3USD tablet
Pms-Amiodarone 200 mg Tablet1.3USD tablet
Ratio-Amiodarone 200 mg Tablet1.3USD tablet
Sandoz Amiodarone 200 mg Tablet1.3USD tablet
Amiodarone 150 mg/3 ml vial0.83USD ml
Pms-Amiodarone 100 mg Tablet0.72USD tablet
Amiodarone 900 mg/18 ml vial0.59USD ml
Amiodarone 450 mg/9 ml vial0.57USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5134127 No1993-01-232010-01-23Us
US6869939 No2002-05-042022-05-04Us
US7635773 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point156Tondeur, R. and Binon, F.; U.S. Patent 3,248,401; April 26,1966; assigned to Societe Beige de I'Azote et des Produits Chimiques du Marly, SA, Belgium.
water solubilityLowNot Available
logP7.57AVDEEF,A (1997)
Predicted Properties
PropertyValueSource
Water Solubility0.00476 mg/mLALOGPS
logP7.24ALOGPS
logP7.64ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)8.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.68 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity145.05 m3·mol-1ChemAxon
Polarizability56.78 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzofurans. These are organic compounds containing a benzene ring fused to a furan. Furan is a five-membered aromatic ring with four carbon atoms and one oxygen atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzofurans
Sub ClassNot Available
Direct ParentBenzofurans
Alternative Parents
Substituents
  • Benzofuran
  • Acetophenone
  • Aryl ketone
  • 3-aroylfuran
  • Phenol ether
  • Benzoyl
  • Iodobenzene
  • Halobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl iodide
  • Aryl halide
  • Heteroaromatic compound
  • Furan
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organoiodide
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wang SP, Wang JA, Luo RH, Cui WY, Wang H: Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1077-84. doi: 10.1111/j.1440-1681.2008.04964.x. Epub 2008 May 25. [PubMed:18505444 ]
  3. Varro A, Biliczki P, Iost N, Virag L, Hala O, Kovacs P, Matyus P, Papp JG: Theoretical possibilities for the development of novel antiarrhythmic drugs. Curr Med Chem. 2004 Jan;11(1):1-11. [PubMed:14754422 ]
  4. Waldhauser KM, Brecht K, Hebeisen S, Ha HR, Konrad D, Bur D, Krahenbuhl S: Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Br J Pharmacol. 2008 Oct;155(4):585-95. doi: 10.1038/bjp.2008.287. Epub 2008 Jul 7. [PubMed:18604229 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Doggrell SA, Brown L: Present and future pharmacotherapy for heart failure. Expert Opin Pharmacother. 2002 Jul;3(7):915-30. [PubMed:12083991 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1H gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1H
Uniprot ID:
O95180
Molecular Weight:
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated calcium channel activity
Specific Function:
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-type calcium channel (CACNA1A), N-type (CACNA1B), L-type (CACNA1C OR CACNA1D) and possibly T-type (CACNA1G). Overexpression induces apoptosis.
Gene Name:
CACNA2D2
Uniprot ID:
Q9NY47
Molecular Weight:
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221 ]
  2. Lewalter T, Pittrow D, Goette A, Kirch W, Hohnloser S: [Clinical pharmacology and electrophysiological properties of dronedarone]. Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S43-7. doi: 10.1055/s-0030-1249208. Epub 2010 Mar 10. [PubMed:20221978 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T: A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. [PubMed:11038157 ]
  4. Website [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Elsherbiny ME, El-Kadi AO, Brocks DR: The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. [PubMed:18445370 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8. [PubMed:8632764 ]
  2. Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13. [PubMed:11231118 ]
  3. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267 ]
  4. Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78. [PubMed:8862725 ]
  5. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 02:39